124 288

Cited 11 times in

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.

Jin, YJ; Lee, JW; Lee, JI; Park, SH; Park, CK; Kim, YS; Jeong, SH; Kim, JH; Hwang, SG; Rim, KS; Yim, HJ; Cheong, JY; Cho, SW; Lee, JS; Park, YM; Jang, JW; Lee, CK; Sohn, JH; Yang, JM; Han, S
BMC gastroenterology, 13:74-74, 2013
Journal Title
BMC gastroenterology
BACKGROUND: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).

METHODS: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.

RESULTS: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7 × 10(5) and >7 × 10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.

CONCLUSIONS: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
MeSH terms
Antiviral Agents/adverse effects/*therapeutic useDrug Therapy, CombinationFemaleHepacivirus/geneticsHepatitis C, Chronic/*drug therapy/virologyHumansInterferon-alpha/adverse effects/*therapeutic useMaleMiddle AgedPolyethylene Glycols/adverse effects/*therapeutic useRecombinant Proteins/adverse effects/therapeutic useRepublic of KoreaRetrospective StudiesRibavirin/therapeutic useViral Load
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
정, 재연조, 성원
Full Text Link
Files in This Item:
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.